Abstract
Patients with hepatocellular carcinoma (HCC) face a common type of cancer, which is amongst the most deadly types of cancer worldwide. The therapeutic options range from curative resection or ablation to loco regional therapies in palliative setting and last but not least, systemic treatment. The latter group underwent major changes in the last decade and a half. Since the introduction of sorafenib in 2007, many other systemic treatments have been investigated. Most without success. It took more than ten years before lenvatinib could be added as alternative first-line treatment option. Just recently a new form of systemic treatment, immunotherapy, entered the field of therapeutic options in patients with HCC. Immune checkpoint inhibitors are becoming the new standard of care in patients with HCC. Several reviews reported on the latest phase 1/2 studies and discussed the higher response rates and better tolerability when compared to current standard of care therapies. This review will focus on elaborating the working mechanism of these checkpoint inhibitors, give an elaborate update of the therapeutic agents that are currently available or under research, and will give an overview of the latest trials, as well as ongoing and upcoming trials.
| Original language | English |
|---|---|
| Article number | 3 |
| Pages (from-to) | 1-23 |
| Number of pages | 23 |
| Journal | Pharmaceuticals |
| Volume | 14 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1 Jan 2021 |
Keywords
- CTLA-4
- Checkpoint inhibition
- Hepatocellular carcinoma (HCC), immunotherapy
- Outcome
- PD-1
- PD-L1
- Systemic therapy
- Tolerability
- Toxicity